Stem cell test a breakthrough in treating heart attacks?

In the trial, published in latest edition of 'The Lancet' journal, cardiac stem cells were used to repair the severely damaged hearts of some 16 patients -- the first time this had ever been done in humans.

After one year, the ejection fraction or "pumping efficiency" of the hearts of eight patients had improved by more than 12 per cent. All patients whose progress was followed underwent some level of recovery. The results tripled the four per cent improvement researchers had expected to see.

Although this was an early stage trial and larger studies are needed, the scientists believe that the promise it shows has huge implications.

"The results are striking. While we do not yet know why the improvement occurs, we have no doubt now that ejection fraction increased and scarring decreased. If these results hold up in future studies, I believe this could be the biggest revolution in cardiovascular medicine," 'The Daily Telegraph' quoted lead scientist Roberto Bolli at Louisville University.

In fact, a total of 23 patients took part in the "Scipio" trial, all of whom had suffered heart failure due to previous heart attack. Sixteen were assigned to the stem cell therapy while the other seven received standard care.

Heart failure occurs when a damaged heart is weakened and unable to pump enough blood around the body. It is commonly caused by a heart attack and can lead to serious disability and a shortened life.

The ground-breaking new treatment involved extracting cardiac stem cells (CSCs) -- self-renewing cells that rebuild hearts and arteries -- from patients during bypass surgery, say the scientists.

The cells were purified and grown in the laboratory before being injected back into damaged regions of patients' hearts four months later. A million CSCs were infused into each patient via a balloon catheter, an expandable device used to open up arteries.

Heart pumping efficiency is assessed by measuring the fraction of blood expelled or "ejected" from left ventricle with each beat. At the start of the study, the patients had an average left ventricular ejection fraction (LVEF) of 40 per cent or lower. Normal LVEF is 50 per cent or higher.

Over a period of four months patients who underwent the treatment saw an 8.5 per cent improvement in LVEF. After one year, this increased to 12.3 per cent. LVEF did not change in seven "control" patients who didn't receive the therapy.

Magnetic Resonance Imaging (MRI) scans conducted on a number of patients showed that scarring in their hearts had been reduced. The small Phase I study was primarily designed to assess safety rather than effectiveness.

Prof Bolli said his team now intended to apply for funding for a much bigger, multi-centre Phase II trial.

Commenting on the study, Professor Gerd Heusch, from the University School of Medicine in Essen, Germany, wrote: "The results from Scipio raise new optimism because the study is based on rigorous quality standards and the reported benefits are of an unexpected magnitude."